BiotechTube
Prolium Bioscience

Prolium Bioscience

San Diego, United States· Est.
proliumbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $54M

Overview

Prolium Bioscience is a private, clinical-stage biotech emerging from stealth in 2026 with a $50 million launch and a focused pipeline in autoimmune disease. Its lead asset, PRO-203, is a CD20xCD3 T-cell engager already in clinical trials with first patients dosed, positioning it as a potential best-in-class therapy. The company operates with a small, dedicated team and a therapeutics business model, currently in a pre-revenue stage as it advances its novel candidates through development.

Autoimmune Disease

Technology Platform

T-cell engager (bispecific antibody) platform targeting B-cells for autoimmune disease, initially focused on CD20xCD3 engagers.

Funding History

2
Total raised:$54M
Venture$50M
Seed$4M

Opportunities

The autoimmune disease market is large and growing, with significant unmet need for more effective and durable therapies.
The application of potent T-cell engager technology, proven in oncology, to autoimmunity represents a novel and potentially disruptive therapeutic approach.
Success with PRO-203 could position Prolium as a leader in this new class of autoimmune therapeutics.

Risk Factors

Major risks include clinical safety concerns specific to T-cell engagers, such as cytokine release syndrome, particularly in autoimmune patients.
The company is highly dependent on the success of a single lead asset (PRO-203), creating significant binary risk.
As a private, early-stage company, it also faces financing risk and intense competition from larger biopharma firms exploring similar modalities.

Competitive Landscape

Prolium competes in the autoimmune B-cell depletion space, which includes established anti-CD20 monoclonal antibodies (e.g., rituximab, ocrelizumab). More directly, it faces competition from other biotechs developing T-cell engagers or related redirected cytotoxicity platforms for autoimmunity. The competitive intensity is high, but the market is large enough to support multiple novel entrants if clinical differentiation is achieved.

More companies in Small Molecule Drugs →More companies in United States →